Inovio Pharmaceuticals Inc Stock Nyse
Equities
US45773H1023
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Financials (USD)
Sales 2024 * | 604K | Sales 2025 * | 8.03M | Capitalization | 262M |
---|---|---|---|---|---|
Net income 2024 * | -99M | Net income 2025 * | -93M | EV / Sales 2024 * | 434 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 32.7 x |
P/E ratio 2024 * |
-2.63
x | P/E ratio 2025 * |
-3.35
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on Inovio Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Jacqueline Shea
CEO | Chief Executive Officer | 58 | 19-03-24 |
Peter Kies
DFI | Director of Finance/CFO | 60 | 02-05-31 |
Chief Tech/Sci/R&D Officer | - | 07-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Simon Benito
CHM | Chairman | 79 | 03-11-30 |
Lota Zoth
BRD | Director/Board Member | 64 | 17-12-31 |
Jay Shepard
BRD | Director/Board Member | 66 | 20-01-14 |
1st Jan change | Capi. | |
---|---|---|
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+47.58% | 40.57B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
+27.16% | 12.05B | |
-3.63% | 11.7B | |
+7.30% | 11.1B |